US-based Warburg Pincus to Acquire Maneesh Pharma in an INR 1,800 Cr Deal

The proposed transaction will focus on the company’s formulations business, particularly its non-tuberculosis (non-TB) portfolio.

US-based private equity firm Warburg Pincus is in advanced talks to acquire a key business unit of Maneesh Pharmaceuticals in a business deal valued at INR 1600 crore to INR 1800 crore.

The proposed transaction will focus on the company’s formulations business, particularly its non-tuberculosis (non-TB) portfolio.

Reportedly, Warburg has already entered into an exclusivity agreement with the promoters of Maneesh Pharmaceuticals and is currently engaged in final-stage negotiations. A formal announcement is expected in the coming months, subject to final agreements and regulatory approvals.

Founded in 1985, Mumbai-based Maneesh Pharmaceuticals has built a presence across multiple therapeutic areas, including gynaecology, anti-infectives, and gastrointestinal treatments.

The company had reported a turnover of INR 500 crore, supported by a diversified product base and steady growth across key segments.

In a parallel development, Warburg Pincus is also reported to be nearing the acquisition of Integrace Health from Temasek and True North for around INR 1200 crore.

The company has been an active investor in India’s pharmaceuticals and healthcare sector. In April 2024, it acquired a majority stake in Chennai-based cataract lens maker Appasamy Associates at a valuation of INR 3,000-3,200 crore.

The new initiative aligns with Warburg’s vision to expand its pharma footprint in India to consolidate two to three India-focused pharmaceutical companies under a single platform.

Stay tuned for more such updates on Digital Health News